Privacy Rule and Family Educational Rights and Privacy Act. The Delphi technique was used to obtain expert input for the coding document. The 131 variable coding instrument received 93.7% agreement and a K-␣ of .791. RESULTS: Including all subsections, 984 laws across localities relate to immunization records. Within and across localities, laws were grouped into 13 topic headings, including health, education, licensing, vital statistics, and insurance. Of 36 (64%) localities that have laws addressing IIS creation, 42% authorize and 58% require development. Locality adoption of these laws increased 50% since the previous study. While 24 (43%) localities have specific IIS laws, 34 (61%) have IIS provisions within other laws. Many others may not specify IIS, but do regulate collection, sharing and/or storage of immunization data within education, department of health or other records. Aggregate data for the localities is presented in tabular format and shaded maps. CONCLUSIONS: Locality IIS policies have increased, HEDIS measures incorporate childhood immunizations, and now Meaningful Use incentives include IIS participation. Expanding adoption of policies encouraging participation may suggest a diffusion of innovation, through both national and state channels. As entrepreneur localities experiment to improve IIS utility and uniformity, it will be important to consider how the current framework has influenced participation, and opportunities for future coordination through policy development.
OBJECTIVES:
Clinical case reports support the occurrence of atypical fractures while Phase III trials for bisphosphonates have not shown this adverse effect. This study determines whether or not atypical fractures of the subtrochanteric region and diaphyseal femur are occurring in bisphosphonate users within the Kentucky Medicaid population. The incidence of atypical femur fractures in bisphosphonate users has been estimated at 30 per 100,000 person years.
1 Bisphosphonates are commonly prescribed for the prevention of osteoporosis-related fractures, 2 but there are concerns about this possible, but rare, adverse event related to the longterm use of bisphosphonates. Patients were excluded if they used a biologic or conventional DMARD prior to their first diagnosis. Patients were categorized as DMARD initiators or non-initiators in the 12 months following diagnosis (follow-up period). We compared demographic and clinical characteristics of initiators versus non-initiators using Cox-proportional hazard models. RESULTS: A total of 26,911 patients met the study criteria; 17,014 patients (63%) initiated a DMARD therapy in the follow-up period. At baseline, compared to initiators, non-initiators were older [mean age 62.6 (SDϭ14.9) versus 58.1 (SDϭ13.3), pϽ0.001], had a higher Deyo-Charlson Comorbidity Index Score (CCI) [0.76 (SDϭ1.3) versus 0.58 (SDϭ1.1), pϽ0.001], were more likely to have had an inpatient stay in the pre-index period (19% versus 13%, pϽ0.001), had higher pre-index total costs [$12, 725 (SDϭ$24, 500) .052]. Multivariate-adjusted risk factors for DMARD non-initiation included older age (85ϩ), high CCI (3ϩ), and the presence of GI disorders, cardiac conditions, hypertension, osteoarthritis, or respiratory infections in the pre-index period. Patients who used an NSAID or corticosteroid, were diabetic, saw a rheumatologist, or had a rheumatoid factor test in the pre-index period were all more likely to initiate a DMARD in the follow-up period. CONCLUSIONS: The majority of new RA patients followed treatment guidelines and initiated a DMARD therapy; nevertheless, over one-third of the patients did not initiate DMARD therapy within a year after diagnosis. 
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